

O

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA

JEFFERY DALE KIVETT, ¹)	Case No. EDCV 13-0013-JPR
)	
Plaintiff,)	
)	MEMORANDUM OPINION AND ORDER
vs.)	AFFIRMING THE COMMISSIONER
)	
CAROLYN W. COLVIN, Acting)	
Commissioner of Social)	
Security, ²)	
)	
Defendant.)	
)	

I. PROCEEDINGS

Plaintiff seeks review of the Commissioner's final decision denying his application for Supplemental Security Income benefits ("SSI"). The parties consented to the jurisdiction of the undersigned U.S. Magistrate Judge pursuant to 28 U.S.C. § 636(c).

¹ The parties have spelled Plaintiff's first name at various times as "Jeffery" and "Jeffrey," and the medical records similarly use both spellings. On January 11, 2013, Plaintiff filed a Notice of Correction of Spelling of Name (Amended), clarifying that "Jeffery" is the proper spelling.

² On February 14, 2013, Colvin became the Acting Commissioner of Social Security. Pursuant to Federal Rule of Civil Procedure 25(d), the Court therefore substitutes Colvin for Michael J. Astrue as the proper Respondent.

1 This matter is before the Court on the parties' Joint
2 Stipulation, filed August 23, 2013, which the Court has taken
3 under submission without oral argument. For the reasons stated
4 below, the Commissioner's decision is affirmed and this action is
5 dismissed.

6 **II. BACKGROUND**

7 Plaintiff was born on November 6, 1959. (Administrative
8 Record ("AR") 74.) He completed 10th grade but did not graduate
9 from high school, and his ability to read and write is limited.
10 (AR 447, 461.) He previously worked as a construction laborer.
11 (AR 441-42, 470-72.) He has a history of drug use, and he was
12 incarcerated from 2005 to 2009 for selling methamphetamine. (AR
13 452-53.) He testified at the hearing that he had not used drugs
14 since his conviction. (AR 452.)

15 On February 3, 2010, Plaintiff filed applications for Social
16 Security disability insurance benefits ("DIB") and SSI. (See AR
17 74-77, 84-91, 425-28.) He alleged that he had been unable to
18 work since June 1, 1998, because of diabetes, lack of feeling in
19 his feet, poor vision, and bleeding ulcers. (AR 74, 80, 85.) He
20 subsequently amended the alleged disability onset date to
21 February 3, 2010, and withdrew his request for DIB. (AR 436-37.)

22 After Plaintiff's applications were denied, he requested
23 reconsideration. (AR 27.) They were again denied, after which
24 he requested a hearing before an ALJ. (AR 30-31, 35-36.) A
25 hearing was held on August 2, 2011, at which Plaintiff, who was
26 represented by counsel, appeared and testified, as did a
27 vocational expert and medical expert Dr. Samuel Landau. (AR 432-
28 53.) In a written decision issued August 5, 2011, the ALJ

1 determined that Plaintiff was not disabled. (AR 11-21.) On
2 November 6, 2012, the Appeals Council denied his request for
3 review. (AR 3-7.) This action followed.

4 **III. STANDARD OF REVIEW**

5 Pursuant to 42 U.S.C. § 405(g), a district court may review
6 the Commissioner's decision to deny benefits. The ALJ's findings
7 and decision should be upheld if they are free of legal error and
8 supported by substantial evidence based on the record as a whole.
9 Id.; Richardson v. Perales, 402 U.S. 389, 401, 91 S. Ct. 1420,
10 1427, 28 L. Ed. 2d 842 (1971); Parra v. Astrue, 481 F.3d 742, 746
11 (9th Cir. 2007). Substantial evidence means such evidence as a
12 reasonable person might accept as adequate to support a
13 conclusion. Richardson, 402 U.S. at 401; Lingenfelter v. Astrue,
14 504 F.3d 1028, 1035 (9th Cir. 2007). It is more than a scintilla
15 but less than a preponderance. Lingenfelter, 504 F.3d at 1035
16 (citing Robbins v. Soc. Sec. Admin., 466 F.3d 880, 882 (9th Cir.
17 2006)). To determine whether substantial evidence supports a
18 finding, the reviewing court "must review the administrative
19 record as a whole, weighing both the evidence that supports and
20 the evidence that detracts from the Commissioner's conclusion."
21 Reddick v. Chater, 157 F.3d 715, 720 (9th Cir. 1996). "If the
22 evidence can reasonably support either affirming or reversing,"
23 the reviewing court "may not substitute its judgment" for that of
24 the Commissioner. Id. at 720-21.

25 **IV. THE EVALUATION OF DISABILITY**

26 People are "disabled" for purposes of receiving Social
27 Security benefits if they are unable to engage in any substantial
28 gainful activity owing to a physical or mental impairment that is

1 expected to result in death or which has lasted, or is expected
2 to last, for a continuous period of at least 12 months. 42
3 U.S.C. § 423(d)(1)(A); Drouin v. Sullivan, 966 F.2d 1255, 1257
4 (9th Cir. 1992).

5 A. The Five-Step Evaluation Process

6 The ALJ follows a five-step sequential evaluation process in
7 assessing whether a claimant is disabled. 20 C.F.R.
8 § 416.920(a)(4); Lester v. Chater, 81 F.3d 821, 828 n.5 (9th Cir.
9 1995) (as amended Apr. 9, 1996). In the first step, the
10 Commissioner must determine whether the claimant is currently
11 engaged in substantial gainful activity; if so, the claimant is
12 not disabled and the claim must be denied. § 416.920(a)(4)(i).
13 If the claimant is not engaged in substantial gainful activity,
14 the second step requires the Commissioner to determine whether
15 the claimant has a "severe" impairment or combination of
16 impairments significantly limiting his ability to do basic work
17 activities; if not, a finding of not disabled is made and the
18 claim must be denied. § 416.920(a)(4)(ii). If the claimant has
19 a "severe" impairment or combination of impairments, the third
20 step requires the Commissioner to determine whether the
21 impairment or combination of impairments meets or equals an
22 impairment in the Listing of Impairments ("Listing") set forth at
23 20 C.F.R., Part 404, Subpart P, Appendix 1; if so, disability is
24 conclusively presumed and benefits are awarded.
25 § 416.920(a)(4)(iii). If the claimant's impairment or
26 combination of impairments does not meet or equal an impairment
27 in the Listing, the fourth step requires the Commissioner to
28 determine whether the claimant has sufficient residual functional

1 capacity ("RFC")³ to perform his past work; if so, the claimant
2 is not disabled and the claim must be denied.
3 § 416.920(a)(4)(iv). The claimant has the burden of proving that
4 he is unable to perform past relevant work. Drouin, 966 F.2d at
5 1257. If the claimant meets that burden, a prima facie case of
6 disability is established. Id. If that happens or if the
7 claimant has no past relevant work, the Commissioner then bears
8 the burden of establishing that the claimant is not disabled
9 because he can perform other substantial gainful work available
10 in the national economy. § 416.920(a)(4)(v). That determination
11 comprises the fifth and final step in the sequential analysis.
12 § 416.920; Lester, 81 F.3d at 828 n.5; Drouin, 966 F.2d at 1257.

13 B. The ALJ's Application of the Five-Step Process

14 At step one, the ALJ found that Plaintiff had not engaged in
15 any substantial gainful activity since February 3, 2010. (AR
16 13.) At step two, she concluded that Plaintiff had severe
17 impairments of "poorly controlled diabetes mellitus," gastritis,
18 and esophagitis. (AR 14.) She determined that Plaintiff's
19 hypertension, "non-obstructing right kidney stone," "right renal
20 calculus," "tobacco dependence," and history of methamphetamine
21 abuse were nonsevere. (Id.) The ALJ further found that
22 Plaintiff had not established through objective evidence a
23 medically determinable ailment of peripheral neuropathy. (Id.)
24 At step three, she determined that his impairments did not meet
25 or equal any of the impairments in the Listing. (Id.) At step

27 ³ RFC is what a claimant can do despite existing
28 exertional and nonexertional limitations. § 416.945; see Cooper
v. Sullivan, 880 F.2d 1152, 1155 n.5 (9th Cir. 1989).

1 four, she found that Plaintiff retained the RFC to perform "less
2 than a full range of light work," with certain additional
3 limitations. (Id.) Based on the VE's testimony, the ALJ
4 concluded that Plaintiff could not perform his past work as a
5 construction worker as generally or actually performed. (AR 18-
6 19.) At step five, she concluded that he was not disabled under
7 the framework of the Medical-Vocational Guidelines, 20 C.F.R.
8 Part 404, Subpart P, Appendix 2, and that jobs existed in
9 significant numbers in the national economy that Plaintiff could
10 perform. (AR 19-20.) Accordingly, the ALJ determined that
11 Plaintiff was not disabled. (AR 20.)

12 **V. RELEVANT FACTS**

13 A. Medical Records

14 On January 29, 2009,⁴ Plaintiff was seen at the emergency
15 room of Oklahoma University Medical Center with complaints of
16 abdominal pain, nausea, and "blood-tinged" vomiting. (AR 175,
17 181.) He was reported to have a past history of diabetes
18 mellitus and peptic ulcer. (AR 175.) He was noted to be
19 suffering from moderate dehydration, severe hyperglycemia, and
20 moderate leukocytosis⁵ and was admitted for observation. (AR

21
22 ⁴ Plaintiff's 2009 medical records predate the amended
23 alleged onset date of February 3, 2010; however, as these records
24 were discussed at the hearing and in the ALJ's decision, they are
25 detailed here. See Williams v. Astrue, 493 F. App'x 866, 868
26 (9th Cir. 2012) (noting that although medical opinions that
predate alleged onset of disability are of limited relevance, ALJ
must consider all medical-opinion evidence (quoting Carmickle v.
Comm'r, Soc. Sec. Admin., 533 F.3d 1155, 1165 (9th Cir. 2008))).

27 ⁵ Leukocytosis is an abnormally large number of
28 leukocytes, or white blood cells, and is observed in cases of
acute infection, inflammation, hemorrhage, and other conditions.

1 177.) Plaintiff was given an MRI and treated with IV fluids, an
2 IV antiemetic, and Zophran⁶ to prevent nausea and vomiting; he
3 also received morphine, Lantus,⁷ and insulin. (AR 179-80.) On
4 January 30, 2009, he was able to tolerate a full ADA diet,⁸ and
5 laboratory studies showed resolution of his anion gap,⁹
6 improvement of his glucose level, and improvement of his blood-
7 urea-nitrogen and creatinine levels. (AR 181.) A chest x-ray
8 performed that day showed no abnormalities in Plaintiff's heart
9 or lungs. (AR 208.) Plaintiff was discharged that day with a

11 See Stedman's Medical Dictionary 991 (27th ed. 2000).

12 ⁶ Zofran is the brand name for ondansetron, used to
13 prevent nausea and vomiting. See Ondansetron, MedlinePlus,
14 <http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601209.html>
(last updated Nov. 15, 2011).

15 ⁷ Lantus is the brand name for insulin glargine, a long-
16 acting synthetic version of human insulin. See Insulin Glargine
17 (rDNA origin) Injection, MedlinePlus, [http://www.nlm.nih.gov/](http://www.nlm.nih.gov/medlineplus/druginfo/meds/a600027.html)
18 <http://www.nlm.nih.gov/medlineplus/druginfo/meds/a600027.html> (last updated Feb. 15,
2012).

19 ⁸ The term "ADA diet" refers to dietary guidelines
20 established by the American Diabetes Association, or ADA, to
21 assist diabetics in maintaining normal blood-sugar levels. See
22 generally Irl B. Hirsch, The Death of the "1800-Calorie ADA
23 Diet," Clinical Diabetes, Apr. 2002, at 51-52, available at
24 <http://clinical.diabetesjournals.org/content/20/2/51.full>. The
25 ADA has clarified that each diabetic must tailor his diet to his
26 individual needs, thus dispelling the notion that a single ADA
27 diet accommodates all diabetics. See The "ADA Diet" Myth,
28 Diabetes Forecast, Mar. 2011, available at [http://www.diabetes](http://www.diabetesforecast.org/2011/mar/the-ada-diet-myth.html)
[forecast.org/2011/mar/the-ada-diet-myth.html](http://www.diabetesforecast.org/2011/mar/the-ada-diet-myth.html). The ADA diet
continues to be used as a benchmark in the treatment of diabetic
patients admitted to the hospital. See Hirsch, supra, at 51-52.

27 ⁹ Anion gap is a calculation of "the difference between
28 the sum of the measured cations and anions in the plasma or
serum." Stedman's Medical Dictionary, supra, at 730. An
elevated anion gap may indicate diabetic or lactic acidosis. Id.

1 prescription for Phenergan¹⁰ "for persistent nausea" and orders
2 to continue his Lantus prescription, continue checking his blood
3 sugar, and adhere to a sliding-scale insulin regimen. (AR 182.)
4 The discharge diagnoses included "nausea and vomiting, resolved,"
5 "abdominal pain, resolved," "hyperglycemia, resolved," "elevated
6 Anion gap/metabolic acidosis, resolved," "uncontrolled diabetes
7 type 2," and "leukocytosis, improved." (AR 181.)

8 On January 31, 2009, Plaintiff returned to the emergency
9 room at OU Medical Center with complaints of vomiting, nausea,
10 and abdominal pain. (AR 183.) A CT scan of Plaintiff's abdomen
11 and pelvis revealed possible esophagitis but was otherwise
12 normal. (AR 206.) A chest x-ray was also normal. (AR 209.)
13 Plaintiff's extremities "exhibit[ed] normal ROM," or range of
14 motion, and he had "[n]o lower extremity edema"; further, he had
15 no motor or sensory deficit. (AR 184.) An electrocardiogram, or
16 ECG, revealed sinus tachycardia but was otherwise normal. (AR
17 214.) Plaintiff was treated with IV fluids, Zofran, morphine,
18 and Phenergan and released. (AR 187, 188.)

19 On September 3, 2009, Plaintiff was seen at the OU Medical
20 Center emergency room with complaints of vomiting blood, black
21 stools, nausea, chronic diarrhea, and abdominal pain. (AR 189.)
22 Plaintiff also complained of difficulty breathing. (Id.) He was
23 admitted, intubated, and treated with morphine, Zofran,
24
25

26 ¹⁰ Phenergan is a brand name for promethazine, whose uses
27 include relaxation and sedation, control of nausea and vomiting,
28 and pain relief. See Promethazine, MedlinePlus, <http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682284.html> (last updated Jan. 1, 2011).

1 Protonix,¹¹ and regular insulin. (AR 194.) A chest x-ray
2 conducted on September 4, 2009, revealed symptoms consistent with
3 chronic obstructive pulmonary disease. (AR 211.) A renal
4 ultrasound conducted the same day was normal. (AR 212.) A
5 history and physical report dated September 4, 2009, reflected
6 past diagnoses of diabetes, peptic ulcer disease, and
7 hypertension. (AR 197.) Plaintiff's then-current medications
8 were reported to include Lantus, regular insulin, clonidine,¹²
9 Reglan,¹³ loperamide,¹⁴ and loratadine.¹⁵ (AR 197-98.) Plaintiff
10 exhibited normal range of motion and no edema in his extremities.
11 (AR 190.) He had no motor or sensory deficit and normal
12 reflexes. (Id.)

13 On September 7, 2009, Plaintiff was discharged. (AR 200.)
14

15 ¹¹ Protonix is a proton pump inhibitor, or "PPI." Laura
16 Dean, Comparing Proton Pump Inhibitors, PubMed Health (Oct. 1,
17 2010), <http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004954/>.
PPIs are medications that block gastric acid production. Id.

18 ¹² Clonidine is used to treat high blood pressure. See
19 Clonidine, MedlinePlus, [http://www.nlm.nih.gov/medlineplus/
20 druginfo/meds/a682243.html](http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682243.html) (last updated Oct. 1, 2010).

21 ¹³ Reglan is a brand name for metoclopramide, used to
22 relieve heartburn, speed healing of esophageal sores and ulcers,
23 and relieve symptoms caused by slow stomach emptying in
diabetics. See Metoclopramide, MedlinePlus, [http://www.nlm.nih.
24 gov/medlineplus/druginfo/meds/a684035.html](http://www.nlm.nih.gov/medlineplus/druginfo/meds/a684035.html) (last updated Sept. 1,
2010).

25 ¹⁴ Loperamide is a nonprescription medication used to
26 control diarrhea. See Loperamide, MedlinePlus, [http://www.nlm.
27 nih.gov/medlineplus/druginfo/meds/a682280.html](http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682280.html) (last updated Aug.
28 1, 2010).

¹⁵ Loratadine is used to treat hayfever symptoms. See
Loratadine, MedlinePlus, [http://www.nlm.nih.gov/medlineplus/
druginfo/meds/a697038.html](http://www.nlm.nih.gov/medlineplus/druginfo/meds/a697038.html) (last updated Oct. 1, 2010).

1 The discharge summary noted that Plaintiff was presumed to be
2 suffering an upper gastrointestinal bleed at the time of
3 admission and was therefore limited to IV ingestion and given
4 Protonix and antiemetics. (Id.) A gastrointestinal specialist
5 suspected Plaintiff might be suffering from esophagitis, but the
6 attending physician chose to delay an upper endoscopy, "instead
7 opting for conservative management while evaluating whether
8 further bleeding was occurring." (Id.) Plaintiff was also
9 treated for hypoglycemia and diabetic ketoacidosis. (Id.)
10 Plaintiff was noted to have a "good" condition at the time of
11 discharge and was instructed to continue with insulin, Protonix,
12 Lantus, and dextrose by IV and to adhere to a diabetic diet.
13 (Id.) A follow-up visit after two weeks was recommended. (Id.)

14 On September 8, 2009, Plaintiff was seen by Drs. Jessica
15 Philpott and Jeremy Moad for a gastrointestinal consult. (AR
16 203.) The doctors recommended a high-dose proton pump inhibitor,
17 multiple fluid boluses,¹⁶ and an insulin drip. (Id.) They also
18 anticipated that Plaintiff might need an upper endoscopy to
19 determine whether his gastrointestinal symptoms were attributable
20 to peptic ulcer disease, esophagitis, or gastritis. (Id.)

21 On December 25, 2009, Plaintiff was seen at the emergency
22 room of St. Mary Medical Center in Apple Valley for complaints of
23 nausea, vomiting, and abdominal pain and was admitted for
24 "diabetic vomiting." (AR 228-29.) He was noted not to be at
25 risk for falls (AR 231), with "motor and sensory grossly intact"
26 (AR 240). A CT scan the same day of Plaintiff's abdomen and

27
28 ¹⁶ A bolus dose indicates a relatively large quantity.
Stedman's Medical Dictionary, supra, at 222.

1 pelvis revealed a "[t]iny hiatal hernia" and a nonobstructing
2 kidney stone. (AR 246, 248.) On December 27, 2009,
3 gastroenterology specialist Dr. Neera Grover examined Plaintiff
4 and noted his "uncontrolled diabetes" but resolving symptoms.
5 (AR 242.) On December 28, 2009, Dr. Grover performed an upper
6 endoscopy to rule out peptic ulcer disease and gastroesophageal
7 reflux disease. (AR 243-44.) The exam revealed "mild to
8 moderate antral gastritis," a hiatal hernia, and "grade 2 to 3
9 linear erosive esophagitis." (AR 245.) Dr. Grover obtained
10 biopsies during the exam. (Id.) She thereafter ordered that
11 Plaintiff could "resume diet" and prescribed Protonix,
12 Carafate,¹⁷ and Reglan. (AR 245.) An abdominal ultrasound was
13 normal. (AR 247.)

14 On December 29, 2009, Plaintiff was discharged. (AR 237.)
15 Plaintiff was noted to be "doing better" after his consultation
16 with Dr. Grover. (Id.) He was instructed to maintain an 1800-
17 calorie ADA diet, continue with Protonix and his "regular other
18 home medications," follow up with his primary-care physician in
19 one week, and follow up with a gastrointestinal specialist in two
20 weeks. (Id.)

21 On March 15, 2010, Plaintiff was seen by Michael Avila, a
22 certified physician assistant, for complaints of "pain [in] both
23 feet," abdominal pain with vomiting, and two weeks of diarrhea,
24 as well as for a consultation on Plaintiff's medications. (Ex.

25
26
27 ¹⁷ Carafate is a brand name for sucralfate, used to treat
28 and prevent peptic ulcers. See Sucralfate, MedlinePlus,
<http://www.nlm.nih.gov/medlineplus/druginfo/meds/a681049.html>
(last updated Aug. 15, 2013).

1 5F at 2.)¹⁸ Plaintiff's current medications were noted to
2 include Lantus and Neurontin. (Id.) Although Mr. Avila noted no
3 abnormalities in Plaintiff's extremities and full range of
4 motion, he found "gross sensory deficit" and "[bilateral]
5 plant[alr] feet non discriminate sharp/dull." (Id.) He assessed
6 Plaintiff as having diabetes mellitus type 2 with neuropathy in
7 both feet. (Id.) It appears that Plaintiff was prescribed
8 Lantus, "regular insulin," a glucometer with lancet and a 30-day
9 supply of chemsticks, as well as gabapentin.¹⁹ (Id.) Mr. Avila
10 ordered testing, including a complete blood count, comprehensive
11 metabolic panel, thyroid-stimulating hormone test,
12 albumin/globulin ratio test, and urinalysis. (Id.) He noted
13 that Plaintiff should monitor his fasting blood sugar, decrease
14 his intake of carbohydrates, increase his intake of protein, and
15 return in one month to follow up. (Id.)

16 On April 6, 2010, Plaintiff was seen by Dr. Damayanthi
17 Seneviratne to follow up regarding the results of Plaintiff's
18 bloodwork. (AR 262.) Plaintiff's current medications were noted
19 to include Lantus and Neurontin. (Id.) Dr. Seneviratne's notes
20 are largely illegible; however, he noted Plaintiff's complaint
21

22
23 ¹⁸ Exhibit 5F does not bear an Administrative Record page
number. It is located between AR 250 and AR 253.

24 ¹⁹ Gabapentin is a prescription medication "sometimes used
25 to relieve the pain of diabetic neuropathy." See Gabapentin,
26 MedlinePlus, <http://www.nlm.nih.gov/medlineplus/druginfo/meds/a694007.html> (last updated July 15, 2011). The brand names for
27 gabapentin include Neurontin (id.), which Plaintiff testified he
28 had taken to treat peripheral neuropathy (AR 455) and
prescriptions for which are reflected in the medical records
(see, e.g., AR 261, 262).

1 that his vision was "deteriorating" and wrote "vision impaired"
2 and "peripheral neuropathy," apparently as complications of
3 Plaintiff's diabetes mellitus. (Id.)

4 On April 13, 2010, Plaintiff again was seen by Dr.
5 Seneviratne for a complaint of high blood sugar and a general
6 medical consult. (Ex. 5F at 1.) Plaintiff's current medications
7 were noted to include Lantus, Neurontin, and regular insulin.
8 (Id.) Dr. Seneviratne's assessment of Plaintiff included
9 "uncontrolled [diabetes mellitus]" and "peripheral neuropathy."
10 (Id.) Dr. Seneviratne's notes appear to have prescribed an
11 increase in Plaintiff's Lantus intake and to have recommended
12 that Plaintiff's blood sugar be checked twice daily.²⁰ (Id.)

13 On April 29, 2010, Plaintiff was seen by Dr. Seneviratne for
14 a consultation on his medications, which were noted to include
15 Lantus, Neurontin, and regular insulin. (AR 261.) Dr.
16 Seneviratne appears to have noted minimally decreased tone and
17 sensation on the part of the form for neurological assessment and
18 to have assessed diabetes mellitus with peripheral neuropathy.
19 (Id.) Dr. Seneviratne also appears to have noted that Plaintiff
20 had been compliant and that his blood sugar readings "have
21 improved"; he renewed Plaintiff's medications. (Id.) Dr.
22 Seneviratne's last note regarding Plaintiff's peripheral
23 neuropathy is largely illegible, but he appears to have
24 recommended Neurontin twice daily. (Id.)

25
26
27 ²⁰ "Bid," which Dr. Seneviratne wrote, is an abbreviation
28 of the Latin expression "bis in die," meaning twice a day. See
Bid Definition, Merriam-Webster Dictionary, www.merriam-webster.com/dictionary/bid (last visited Oct. 28, 2013).

1 On June 6, 2010, Plaintiff was seen in the emergency room of
2 St. Mary Regional Medical Center for complaints of nausea and
3 vomiting. (AR 301.) Plaintiff said that he had been "working
4 outside in the heat" when the nausea and vomiting began and that
5 these symptoms had continued for two days. (Id.) Plaintiff was
6 admitted with "[d]ehydration with nonketotic hyperosmolar
7 hyperglycemia."²¹ (Id.) At the time of admission, lab data
8 showed Plaintiff's glucose to be 497²² and his bicarbonate level
9 to be 16.²³ (AR 306.) A "limited" chest x-ray was reported to
10 show no abnormalities in Plaintiff's lungs or heart. (AR 305.)
11 He was treated with IV fluids, insulin, and Protonix, and his
12 condition "rapidly improved." (AR 303, 306-07.) Once again, he
13 was noted not to be at risk of falling (AR 361), and he had "no
14

15 ²¹ "Diabetic hyperglycemic hyperosmolar syndrome (HHS) is
16 a complication of type 2 diabetes that involves extremely high
17 blood sugar (glucose) levels without the presence of ketones.
18 Ketones are byproducts of fat breakdown." Diabetic hyperglycemic
19 hyperosmolar syndrome, MedlinePlus, [http://www.nlm.nih.gov/
20 medlineplus/ency/article/000304.htm](http://www.nlm.nih.gov/medlineplus/ency/article/000304.htm) (last updated June 12, 2012).

21 ²² Target blood glucose levels for people with diabetes
22 are between 70 and 130 mg/dL before meals and below 180 mg/dL one
23 to two hours after the start of a meal. See Prevent diabetes
24 problems: Keep your diabetes under control, Nat'l Diabetes
25 Information Clearinghouse (NDIC), [http://diabetes.niddk.nih.gov/
26 dm/pubs/complications_control/#numbers](http://diabetes.niddk.nih.gov/dm/pubs/complications_control/#numbers) (last updated Aug. 8,
27 2013). Hyperglycemia, or high blood sugar, begins to cause
28 symptoms when glucose values become "significantly elevated,"
exceeding 200 mg/dL. Hyperglycemia in diabetes, Mayo Clinic,
[http://www.mayoclinic.com/health/hyperglycemia/DS01168/
METHOD=print](http://www.mayoclinic.com/health/hyperglycemia/DS01168/METHOD=print) (last updated June 14, 2012).

26 ²³ The normal blood bicarbonate range is 23-29 mEq/L
27 (milliequivalent per liter). CO2 blood test, MedlinePlus,
28 <http://www.nlm.nih.gov/medlineplus/ency/article/003469.htm> (last
updated Apr. 29, 2012). Lower than normal levels of bicarbonate
can be a sign of ketoacidosis, among other ailments. Id.

1 focal deficit" with "fairly well preserved" "[m]otor tone" (AR
2 366).

3 On June 7, 2010, Plaintiff's anticipated discharge was
4 delayed by his resumed nausea and vomiting. (AR 301.) Because
5 Plaintiff "was noted to have several episodes of coffee-ground
6 emesis"²⁴ following admission, a consultation with a
7 gastrointestinal specialist was ordered. (AR 308.) An upper
8 endoscopy showed evidence of acute gastritis, a Mallory-Weiss
9 tear,²⁵ a possible benign gastric polyp, and a hiatal hernia.
10 (AR 301, 311, 323.) The Mallory-Weiss tear was treated with
11 injections of epinephrine, which was noted to effectively address
12 bleeding in the area. (AR 312.) Lab tests confirmed that the
13 probable polyp was benign. (AR 313.)

14 On June 8, 2010, Plaintiff was noted to have "developed a
15 low-grade fever" overnight. (AR 321.) He was also noted to have
16 continued nausea, vomiting, and diarrhea. (Id.) Plaintiff was
17 to be tested for a bacterial infection, undergo an abdominal
18 ultrasound "to rule out gallstones," undergo an abdominal CT scan
19 "to rule out obstruction," and be tested to confirm the levels of
20

21 ²⁴ "Hematemesis is the vomiting of blood, which may be
22 obviously red or have an appearance similar to coffee grounds."
23 See H. Kenneth Walker, W. Dallas Hall & J. Willis Hurst, Clinical
24 Methods: The History, Physical, and Laboratory Examinations 439
(3d ed. 1990), available at [http://www.ncbi.nlm.nih.gov/
books/NBK411/](http://www.ncbi.nlm.nih.gov/books/NBK411/).

25 ²⁵ A Mallory-Weiss tear is a tear in the mucus membrane of
26 the lower esophagus or upper stomach near where the organs join.
27 See Mallory-Weiss tear, MedlinePlus, [http://www.nlm.nih.gov/
medlineplus/ency/article/000269.htm](http://www.nlm.nih.gov/medlineplus/ency/article/000269.htm) (last updated Nov. 11, 2010).
28 Such tears "are usually caused by forceful or long-term vomiting
or coughing." Id.

1 amylase and lipase in his blood. (AR 321-22.) He had no
2 cyanosis of the extremities.²⁶ (AR 371.) His prognosis was
3 reported to be "guarded." (AR 322.)

4 The same day, a CT scan of Plaintiff's abdomen and pelvis
5 showed evidence of subsegmental atelectasis,²⁷ a "small hiatal
6 hernia," and "[a] 2 mm, nonobstructing stone" in Plaintiff's
7 right kidney. (AR 333.) Plaintiff's other visible organs
8 appeared normal. (*Id.*) A "limited" abdominal ultrasound also
9 was reported to be normal. (AR 336.)

10 On June 9, 2010, Plaintiff was reported to be in sinus
11 rhythm, tolerating clear liquids, and not having any nausea or
12 vomiting. (AR 382.) An imaging report dated June 10, 2010,
13 showed that Plaintiff's "lungs and pleura are clear" and his
14 "heart and mediastinum are normal." (AR 332.)

15 Plaintiff was discharged on June 11, 2010. Discharge notes
16 reflect that he was treated with PPIs and Carafate. (AR 301.)
17 He was advised to avoid alcohol and nonsteroidal anti-
18 inflammatory drugs,²⁸ limit his diet to 1800 calories a day, and
19 follow up within a week with his primary-care physician. (AR
20

21
22 ²⁶ Cyanosis is a discoloration of the skin arising from
23 poor circulation. See Skin discoloration - bluish, MedlinePlus,
24 <http://www.nlm.nih.gov/medlineplus/ency/article/003215.htm> (last
25 updated Apr. 21, 2013).

26 ²⁷ Subsegmental atelectasis is partial collapse of the
27 lung. Stedman's Medical Dictionary, *supra*, at 160.

28 ²⁸ Nonsteroidal anti-inflammatory drugs, or NSAIDs,
relieve pain by blocking the production of pain-signaling
molecules. See Laura Dean, Comparing NSAIDs, PubMed Clinical Q&A
(May 1, 2011), <http://www.ncbi.nlm.nih.gov/books/NBK45590/>.
Common NSAIDs include aspirin and ibuprofen. *Id.*

1 301-02.)

2 On June 15, 2010, Plaintiff was seen by Dr. Seneviratne.
3 (AR 275.) Plaintiff was noted to have been admitted to St. Mary
4 Medical Center on June 6, 2010, and to be complaining of fatigue,
5 headache, and weakness. (Id.) This record is largely illegible
6 but reflects further notes regarding Plaintiff's endoscopy and
7 diabetes. (Id.)

8 On October 10, 2010, Plaintiff was seen by a certified
9 physician assistant for a consultation regarding his medications.
10 (AR 349.) He was noted to have diabetes mellitus and "neuropathy
11 lower legs." (Id.) The remainder of the examining provider's
12 notes are largely illegible.

13 On November 10, 2010, Plaintiff was seen by Dr. Seneviratne
14 for complaints of fatigue and stomach pain. (AR 350.) His notes
15 appear to state that Plaintiff's feet were cold to the touch and
16 that he experienced decreased sensation. (Id.) The notes appear
17 further to state that Plaintiff suffers from diabetes mellitus,
18 "not controlled," and peripheral neuropathy. (Id.) Plaintiff
19 was instructed to check his blood sugar twice daily and provide
20 the readings, and he was referred to a podiatrist. (Id.)

21 On March 6, 2011, Plaintiff was seen in the emergency room
22 of St. Mary Regional Medical Center for complaints of nausea,
23 vomiting, and abdominal pain lasting two days. (AR 281.) He was
24 found to have "a very elevated glucose of 345," "a bicarb of 14,"
25 "a high anion gap metabolic acidosis," and leukocytosis and was
26 admitted for diabetic ketoacidosis. (Id.) His chart notes
27 additional "[d]iagnoses" of nausea, vomiting, and "right renal
28 calculus." (Id.) Plaintiff was noted to have undergone a CT

1 scan of his abdomen and pelvis and a chest x-ray. (AR 408.)
2 Plaintiff "responded well to IV fluids," insulin, and Levaquin²⁹
3 and was discharged on March 9, 2011, at which point he tolerated
4 solid food and had stable vital signs. (AR 281.) Plaintiff was
5 instructed to adhere to a "low fat, low salt, ADA 2000
6 kilocalorie per day diet" and to meet with his primary-care
7 physician within two weeks. (Id.) Once again, Plaintiff was
8 noted to have no cyanosis of the extremities. (AR 407.)

9 On March 15, 2011, Plaintiff was seen by Dr. Seneviratne for
10 complaints of stomach pain and inability to control his blood
11 sugar, problems that reportedly had lasted three to four weeks.
12 (AR 351.) Dr. Seneviratne's notes are largely illegible but
13 appear to pertain to Plaintiff's blood sugar and abdominal
14 issues. No mention of peripheral neuropathy is evident. (Id.)

15 On April 27, 2011, Plaintiff was seen by Dr. Seneviratne for
16 complaints of black toes lasting 10 days, feeling of numbness
17 lasting 20 days, and "really high" blood sugar lasting 20 days.
18 (AR 352.) Dr. Seneviratne's notes are largely illegible, but he
19 appears to have noted swelling in Plaintiff's lower extremities,
20 and his assessment reflects at least a suspicion of "cellulitis"
21 and a prescription. (Id.)

22 On May 4, 2011, Plaintiff was seen by Dr. Seneviratne to
23 consult regarding his medications and to address paperwork. (AR
24 354.) Dr. Seneviratne noted "bilateral [decreased] sensation of
25

26
27 ²⁹ Levaquin is the brand name for the antibiotic
28 levofloxacin. See Levofloxacin, MedlinePlus, <http://www.nlm.nih.gov/medlineplus/druginfo/meds/a697040.html> (last updated Sept. 15, 2013).

1 both feet" and peripheral neuropathy. (Id.) The same day, Dr.
2 Seneviratne handwrote the following on a prescription pad:

3 To whom it may concern

4 Mr. Kivett has uncontrolled Diabetes Mellitus

5 His blood sugars are Very High and we are working
6 on him to control his Diabetes

7 Thanks

8 [Signature]

9 (AR 279.)

10 Plaintiff was admitted to St. Mary Medical Center on July
11 19, 2011. (AR 423.) On July 21, 2011, Plaintiff was discharged
12 with prescriptions for Protonix, lisinopril,³⁰ and
13 ciprofloxacin.³¹ (AR 422.) Plaintiff was instructed to maintain
14 a salt-restricted diet and to follow up with a physician within a
15 week. (Id.)

24 ³⁰ Lisinopril is used to treat high blood pressure. See
25 Lisinopril, MedlinePlus, [http://www.nlm.nih.gov/medlineplus/
26 druginfo/meds/a692051.html](http://www.nlm.nih.gov/medlineplus/druginfo/meds/a692051.html) (last updated Sept. 15, 2012).

27 ³¹ Ciprofloxacin is used to treat or prevent certain
28 bacterial infections. See Ciprofloxacin, MedlinePlus,
<http://www.nlm.nih.gov/medlineplus/druginfo/meds/a688016.html>
(last updated Sept. 15, 2013).

1 complaints of vomiting of blood and history of peptic ulcer
2 disease; Plaintiff's gastrointestinal consultation on September
3 8, 2009; and Plaintiff's admission to St. Mary Medical Center on
4 December 25, 2009, for complaints of abdominal pain, vomiting,
5 and nausea. (Id.) The Case Analysis confirmed that Plaintiff's
6 diabetes was "not well controlled" but found "no evidence of
7 complications or organ damage." (Id.) The Case Analysis further
8 noted that Plaintiff's "gastritis, esophagitis, and history of
9 ulcer disease have not resulted in malnutrition or significant
10 anemia." (Id.) Accordingly, Plaintiff was found to "retain[]
11 the RFC for light work." (Id.)

12 On August 26, 2010, medical consultant Dr. G. Taylor-Holmes,
13 a specialist in internal medicine, performed a Case Analysis.
14 (AR 276.) Dr. Taylor-Holmes noted Dr. Hartman's prior Case
15 Analysis and findings and reviewed additional records received
16 from Dr. Seneviratne's clinic. (Id.) Dr. Taylor-Holmes noted
17 "DM w/ peripheral neuropathy" based on Plaintiff's April 29,
18 2010, consultation with Dr. Seneviratne. (Id.) Dr. Taylor-
19 Holmes affirmed Dr. Hartman's finding that Plaintiff retained the
20 RFC for light work. (Id.)

21 C. Hearing Testimony

22 At the August 2, 2011 hearing before the ALJ, Plaintiff
23 testified that he completed 10th grade but left high school
24 during his 11th-grade year. (AR 447.) Plaintiff stated that he
25 completed his high-school coursework through the special-
26 education program because of his poor literacy. (Id.) Plaintiff
27 testified that he had been able to maintain employment despite
28 his limited literacy. (AR 461-62.) He stated that he received

1 help with job applications from his nephew or "whoever's around."
2 (AR 461.) He was able to bathe and dress himself without
3 assistance and prepare meals for himself. (AR 449-50.)
4 Plaintiff did not have a driver's license at the time of the
5 hearing because it was suspended for reasons unrelated to his
6 alleged impairments, he had not sought to renew his license, and
7 his inability legally to drive had not prevented him from
8 maintaining employment. (AR 450-51.)

9 Plaintiff stated that he was convicted of selling
10 methamphetamine and incarcerated from 2005 until November 2009.
11 (AR 452-53.) He testified that he had not used the drug since
12 2005. (Id.) He did not work while incarcerated because of his
13 health issues - specifically, his poorly controlled diabetes,
14 stomach problems, and fatigue. (AR 454.) Plaintiff testified
15 that while incarcerated, he took medication to treat his stomach,
16 control vomiting, and treat fatigue. (AR 455.) He testified
17 that he also took Neurontin for the pain in his feet. (Id.)
18 Plaintiff also confirmed that he has been taking blood-pressure
19 medication "all along"; it is unclear from the transcript when
20 such medication first was prescribed. (AR 456.)

21 Plaintiff testified that he previously worked as a laborer.
22 (AR 442.) He stated that he began working for a company that
23 pours cement forms while living in a halfway house following his
24 incarceration. (AR 453-54.) He testified that he was terminated
25 after about a month when he lost consciousness because of an
26 imbalance in blood sugar. (AR 441.) He confirmed that he had
27 looked for a variety of work since his release from prison,
28 including gardening and carpentry work. (AR 454.)

1 Plaintiff stated that his peripheral neuropathy caused him
2 to be unable to feel his feet, which he testified are "just numb
3 all the time," extending to his knees. (AR 456.) He stated that
4 he also suffered from buzzing, tingling, and sharp pains in his
5 feet and lower legs. (AR 456-57.) When asked how the problem
6 with his feet affected his ability to work, Plaintiff stated that
7 "I can't feel my feet to walk half the time" and confirmed that
8 he had stumbled "a couple of times." (AR 457.) Plaintiff
9 testified that he had never used a cane or walker, although when
10 asked whether he had ever used "[a]ny other device to assist you
11 walking," Plaintiff stated, "I guess I have a couple of times
12 because . . . every now and then it's so numb that . . . I
13 stumble." (Id.)

14 Plaintiff testified that his diabetes interfered with his
15 ability to work by causing bouts of nausea every three to four
16 days and uncontrolled vomiting approximately every three months,
17 requiring a visit to the hospital. (AR 457-58.) Plaintiff
18 stated that he was often able to stifle uncontrolled vomiting by
19 regulating his blood sugar. (AR 458.) Plaintiff further
20 testified that he suffered from near-constant fatigue that
21 required him to lie down once or twice a day. (AR 459-60.)

22 Dr. Samuel Landau, a physician board-certified in both
23 internal medicine and cardiovascular disease, appeared at the
24 hearing as a medical expert. (AR 435.) Dr. Landau testified
25 that Plaintiff's medically determinable impairments included
26 "poorly controlled diabetes mellitus," gastritis, esophagitis,
27 and right renal calculus. (AR 462.) He stated that Plaintiff's
28 ailments did not meet a Listing. (AR 464.) Dr. Landau noted

1 that although Plaintiff testified to hospitalization
2 approximately every three months, the record reflected less
3 frequent hospitalization. (Id.)

4 Dr. Landau opined that Plaintiff's diabetes would impose
5 some limitations upon his capacity to work. He testified that
6 Plaintiff would be able to stand, walk, or sit for six hours each
7 in an eight-hour day and would require breaks every two hours.
8 (AR 466.) He stated that Plaintiff could lift and carry 25
9 pounds frequently and 50 pounds occasionally. (Id.) He
10 testified that Plaintiff could climb stairs but not ladders and
11 should not work at heights or in situations requiring him to
12 balance. (Id.) He stated that Plaintiff should work in a
13 temperature-controlled environment. (Id.)

14 Dr. Landau confirmed that the nausea and vomiting from which
15 Plaintiff had suffered were consistent with his poorly controlled
16 diabetes mellitus but that Plaintiff "also has underlying
17 digestive diseases in addition to that." (AR 467-68.)

18 He testified that he did not find any "objective evidence of
19 peripheral neuropathy" in Plaintiff's medical records. (AR 466.)
20 He believed the diagnoses of peripheral neuropathy in the record
21 were based on symptoms alone, without objective testing. (AR
22 467.) Dr. Landau stated that to establish such a diagnosis, an
23 examination must be performed to establish "abnormalities" such
24 as "sensory abnormalities, dependent reflex changes, vibratory
25 sense change, weakness, atrophy." (AR 466-67.) He noted that
26 "electrodiagnostic studies" exist to confirm such a diagnosis but
27 none had been performed on Plaintiff. (AR 467.)

28 Dr. Landau found no support in Plaintiff's medical record

1 for Plaintiff's claim that his medical impairments prevented him
2 from maintaining full-time employment. (AR 468.) He noted that
3 the record reflected four hospitalizations for treatment of
4 Plaintiff's diabetes but stated, "[W]hy the diabetes control is
5 so poor, I can't tell you." (AR 469.)

6 D. ALJ's Decision

7 In her August 5, 2011 decision, the ALJ found that Plaintiff
8 had severe impairments of poorly controlled diabetes mellitus,
9 gastritis, and esophagitis. (AR 14.) She found that peripheral
10 neuropathy was not a medically determinable impairment "due to a
11 lack of objective evidence," citing Dr. Landau's testimony.

12 (Id.)

13 The ALJ determined that Plaintiff retained the RFC to
14 perform "less than a full range of light work."³³ (Id.)

15 Specifically, the claimant can lift and/or carry ten
16 pounds frequently and twenty pounds occasionally; he can
17 stand and/or walk six hours, sit two hours in an eight
18 hour workday; the claimant cannot climb ladders, ropes,
19 or scaffolds or work at unprotected heights; and the
20 claimant must avoid concentrated exposure to extreme
21 cold, extreme heat, and extreme weather.

22 (Id.) In so finding, the ALJ considered all of Plaintiff's

23
24 ³³ "Light work" involves "lifting no more than 20 pounds
25 at a time with frequent lifting or carrying of objects weighing
26 up to 10 pounds." § 416.967(b). "Even though the weight lifted
27 may be very little, a job is in this category when it requires a
28 good deal of walking or standing, or when it involves sitting
most of the time with some pushing and pulling of arm or leg
controls." Id. "To be considered capable of performing a full
or wide range of light work, [a claimant] must have the ability
to do substantially all of these activities." Id.

1 symptoms and found his "allegations not fully credible" to the
2 extent his alleged limitations were inconsistent with both his
3 own testimony about his activities and the medical evidence of
4 record. (AR 15-16.)

5 The ALJ "assigned significant, but not great, weight" to Dr.
6 Landau's testimony in determining Plaintiff's RFC. (AR 17.) As
7 the ALJ noted, Dr. Landau "is board-certified in internal
8 medicine and cardiovascular disease, he has an awareness of all
9 the medical evidence in the record, and he understands Social
10 Security disability programs and requirements." (Id.) The ALJ
11 found more restricted functional limitations than those assessed
12 by Dr. Landau, based in part upon Plaintiff's subjective
13 complaints. (AR 18.) The ALJ also "accorded some, but not
14 significant, weight" to the findings of the state medical
15 consultants. (Id.) She found that "[a]dditional evidence added
16 to the record after [their RFC] determination, including the
17 claimant's hearing testimony, establishes the presence of more
18 restrictive limitations" than those assessed by the medical
19 consultants. (Id.)

20 The ALJ found that Plaintiff's RFC was insufficient to
21 enable him to perform his past relevant work. (AR 18-19.) Given
22 Plaintiff's age, education, work experience, and RFC, she found
23 that jobs "exist[ed] in significant numbers in the national
24 economy that the claimant can perform." (AR 19.) The ALJ
25 therefore held that Plaintiff was not under a disability from the
26 amended alleged onset date of February 3, 2010, through the date
27 of her decision. (AR 20.)

1 **VI. DISCUSSION**

2 Plaintiff alleges that the ALJ erred in evaluating (1) the
3 medical evidence of record, specifically, his diagnosis of
4 peripheral neuropathy,³⁴ and (2) Plaintiff's credibility. (J.
5 Stip. at 4.) Neither of these contentions warrants reversal.

6 A. The ALJ Properly Evaluated the Medical Evidence

7 Plaintiff contends that the ALJ erred in finding that
8 Plaintiff failed to establish a severe medically determinable
9 impairment of peripheral neuropathy. (J. Stip. at 7.) As a
10 result, Plaintiff argues, the ALJ erred in finding that Plaintiff
11 retained the RFC to perform less than a full range of light work.
12 (Id.) Reversal is not warranted.

13 1. The ALJ did not err in finding that the medical
14 evidence failed to establish a severe, medically
15 determinable impairment of peripheral neuropathy

16 Plaintiff argues that the ALJ "failed to properly consider
17 Plaintiff's diabetic neuropathy." (J. Stip. at 4.) Plaintiff
18 maintains that the medical record provides objective evidence
19 supporting a diagnosis of peripheral neuropathy and the ALJ erred
20 in accepting Dr. Landau's testimony to the contrary. (J. Stip.
21 at 6-7.)

22 a. *Applicable Law*

23 At step two of the sequential evaluation process, the
24 claimant has the burden to show that he has one or more "severe"
25 medically determinable impairments that can be expected to result
26

27 ³⁴ Plaintiff does not argue that the ALJ erred in finding
28 him not disabled based on the impairments she found to be
medically determinable.

1 in death or last for a continuous period of at least 12 months.
2 See Bowen v. Yuckert, 482 U.S. 137, 146 n.5, 107 S. Ct. 2287,
3 2294 n.5, 96 L. Ed. 2d 119 (1987) (claimant bears burden at step
4 two); Celaya v. Halter, 332 F.3d 1177, 1180 (9th Cir. 2003)
5 (same); 20 C.F.R. §§ 416.908 (defining "physical or mental
6 impairment"), 416.920(a)(4)(ii) (claimants will be found not
7 disabled at step two if they "do not have a severe medically
8 determinable physical or mental impairment that meets the
9 duration requirement"). A medically determinable impairment must
10 be established by signs, symptoms, or laboratory findings; it
11 cannot be established based solely on a claimant's own statement
12 of his symptoms. § 416.908; Ukolov v. Barnhart, 420 F.3d 1002,
13 1004-05 (9th Cir. 2005); SSR 96-4p, 1996 WL 374187, at *1 (July
14 2, 1996); see also 42 U.S.C. § 423(d)(3) ("physical or mental
15 impairment" is one that "results from anatomical, physiological,
16 or psychological abnormalities which are demonstrable by
17 medically acceptable clinical and laboratory diagnostic
18 techniques"). A "medical sign" is "an anatomical, physiological,
19 or psychological abnormality that can be shown by medically
20 acceptable clinical diagnostic techniques." Ukolov, 420 F.3d at
21 1005 (quoting SSR 96-4p, 1996 WL 374187, at *1 n.2 (July 2, 1996)
22 (internal quotation marks omitted)); accord 20 C.F.R.
23 § 416.928(b).

24 To establish that a medically determinable impairment is
25 "severe," moreover, the claimant must show that it "significantly
26 limits [his] physical or mental ability to do basic work
27
28

1 activities."³⁵ § 416.920(c); accord § 416.921(a). "An
2 impairment or combination of impairments may be found not severe
3 only if the evidence establishes a slight abnormality that has no
4 more than a minimal effect on an individual's ability to work."
5 Webb v. Barnhart, 433 F.3d 683, 686 (9th Cir. 2005) (emphasis in
6 original, internal quotation marks omitted); see also Smolen v.
7 Chater, 80 F.3d 1273, 1290 (9th Cir. 1996) ("[T]he step-two
8 inquiry is a de minimis screening device to dispose of groundless
9 claims."). Applying the applicable standard of review to the
10 requirements of step two, a court must determine whether an ALJ
11 had substantial evidence to find that the medical evidence
12 clearly established that the claimant did not have a medically
13 severe impairment or combination of impairments. Webb, 433 F.3d
14 at 687.

15 b. *Analysis*

16 Plaintiff has failed to meet his burden to present evidence
17 of medical signs, symptoms, and laboratory findings establishing
18 his alleged peripheral neuropathy as a medically determinable
19 impairment. Plaintiff points to five "Progress Notes" that
20 document consultations by Dr. Seneviratne and a physician
21 assistant regarding Plaintiff's diabetes and related ailments,
22 including peripheral neuropathy. (J. Stip. at 5.) Although the
23

24 ³⁵ "Basic work activities" include, among other things,
25 "[p]hysical functions such as walking, standing, sitting,
26 lifting, pushing, pulling, reaching, carrying, or handling";
27 "[c]apacities for seeing, hearing, and speaking";
28 "[u]nderstanding, carrying out, and remembering simple
instructions"; using judgment; "[r]esponding appropriately to
supervision, co-workers and usual work situations"; and
"[d]ealing with changes in a routine work setting." 20 C.F.R. §
416.921(b); accord Yuckert, 482 U.S. at 141.

1 notes in each case reference peripheral neuropathy or treatment
2 with Neurontin, none indicate the completion of any medically
3 accepted diagnostic test to confirm the diagnosis. (See Ex. 5F
4 at 1, 2; AR 262, 350, 354.) Rather, these records appear merely
5 to record Plaintiff's complained-of symptoms of pain and
6 numbness. Symptoms alone are insufficient to establish a
7 medically determinable impairment. See Ukolov, 420 F.3d at 1005-
8 06 (treating physician's notation of balance problems, dizziness,
9 problems with "sustained ambulation," and increased tendency to
10 fall did not support finding of impairment because they were
11 based "solely" on plaintiff's own "perception or description of
12 his problems" (internal quotation marks omitted)); 20 C.F.R. §
13 416.908 ("A physical or mental impairment must be established by
14 medical evidence consisting of signs, symptoms, and laboratory
15 findings, not only by your statement of symptoms."); SSR 96-4p,
16 1996 WL 374187, at *1 (July 2, 1996) ("[R]egardless of how many
17 symptoms an individual alleges, or how genuine the individual's
18 complaints appear to be, the existence of a medically
19 determinable physical or mental impairment cannot be established
20 in the absence of objective medical abnormalities; i.e., medical
21 signs and laboratory findings.").

22 Diagnosis of peripheral neuropathy is "difficult" and
23 generally requires "[a] thorough neurological examination,"
24 "extensive patient history," tests to identify the cause of the
25 disorder, and tests to determine the extent and type of nerve
26 damage. See Peripheral Neuropathy Fact Sheet, Nat'l Inst. of
27 Neurological Disorders & Stroke, [http://www.ninds.nih.gov/
28 disorders/peripheralneuropathy/detail_peripheralneuropathy.htm](http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm)

1 (last updated Sept. 19, 2012); (see also AR 466-67 (Dr. Landau
2 noting that diagnosis requires examination to establish
3 "abnormalities" such as "sensory abnormalities, dependent reflex
4 changes, vibratory sense change, weakness, atrophy")). Further
5 testing is sometimes required to determine the nature and extent
6 of the neuropathy. See Peripheral Neuropathy Fact Sheet, supra;
7 (see also AR 467.) Nothing in the record indicates that Dr.
8 Seneviratne - or any other doctor - ever conducted a "thorough
9 neurological examination" or performed any tests on Plaintiff at
10 all, much less sufficient to diagnose peripheral neuropathy. The
11 only even arguable medical signs in the record supporting the
12 diagnosis are brief notations on March 15, 2010, and May 4, 2011,
13 that Plaintiff had decreased sensation in his feet and a November
14 10, 2010 notation that his feet were cold. But Plaintiff's
15 hospital records of the same general time frame belie these
16 conclusory observations, which may well simply be notations of
17 Plaintiff's subjective symptoms. In June 2010, the hospital
18 noted that he was not at risk of falling, had no focal deficit,
19 and had "fairly well preserved" motor tone. (AR 361, 366.) He
20 also had no cyanosis of the extremities. (AR 371.) In March
21 2011, the hospital noted once again that he had no cyanosis of
22 the extremities. (AR 401.) Further, Plaintiff's original
23 diagnosis of peripheral neuropathy came from a physician
24 assistant, not a medically acceptable source. See Molina v.
25 Astrue, 674 F.3d 1104, 1111 (9th Cir. 2012) (physician assistants
26 are not "[a]cceptable medical sources" (alteration in original,
27 internal quotation marks omitted)); Thornton v. Astrue,
28 CV-09-0138-CI, 2010 WL 1904661, at *5 (E.D. Wash. May 12, 2010)

1 (noting that physician assistant's opinion cannot establish
2 medically determinable impairment (citing 20 C.F.R. § 416.913(d);
3 SSR 06-03p, 2006 WL 2329939 (Aug. 9, 2006))).

4 Nor is there any other evidence in the record of a diagnosis
5 of peripheral neuropathy based upon medically acceptable
6 diagnostic techniques. Although Plaintiff testified that he has
7 taken Neurontin since he was incarcerated in 2005 (AR 455; see
8 also AR 451), the only references to peripheral neuropathy in the
9 record are the more recent ones discussed above. Moreover,
10 Neurontin is used to treat other ailments, including restless-
11 legs syndrome. See Gabapentin, MedlinePlus, <http://www.nlm.nih.gov/medlineplus/druginfo/meds/a694007.html> (last updated July 15,
12 2011).
13

14 Further, to the extent the ALJ relied upon Dr. Landau's
15 testimony that the medical record contained no objective evidence
16 of peripheral neuropathy, that testimony was consistent with the
17 medical record and the ALJ was entitled to rely upon it. See
18 Thomas v. Barnhart, 278 F.3d 947, 957 (9th Cir. 2001) ("The
19 opinions of non-treating or non-examining physicians may also
20 serve as substantial evidence when the opinions are consistent
21 with independent clinical findings or other evidence in the
22 record."); Morgan v. Comm'r of Soc. Sec. Admin., 169 F.3d 595,
23 600 (9th Cir. 1999) ("Opinions of a nonexamining, testifying
24 medical advisor may serve as substantial evidence when they are
25 supported by other evidence in the record and are consistent with
26 it" (citing Andrews v. Shalala, 53 F.3d 1035, 1041 (9th Cir.
27 1995))); 20 C.F.R. § 416.927(c)(4) (ALJ will generally give more
28 weight to opinions that are "more consistent . . . with the

1 record as a whole"). Moreover, the ALJ could credit Dr. Landau's
2 opinion because he testified at the hearing and was subject to
3 cross-examination. See Andrews, 53 F.3d at 1042 (greater weight
4 may be given to nonexamining doctors who are subject to
5 cross-examination). Any conflict in the properly supported
6 medical-opinion evidence was therefore the sole province of the
7 ALJ to resolve. See id. at 1041.

8 Because the record does not reflect diagnosis of Plaintiff's
9 alleged peripheral neuropathy by medically acceptable clinical
10 and laboratory diagnostic techniques, the ALJ did not err in
11 holding that the record lacked objective evidence sufficient to
12 establish a medically determinable impairment of peripheral
13 neuropathy. (AR 14); see Ukolov, 420 F.3d at 1005-06; 42 U.S.C.
14 § 423(d)(3) ("[A] 'physical or mental impairment' is an
15 impairment that results from anatomical, physiological, or
16 psychological abnormalities which are demonstrable by medically
17 acceptable clinical and laboratory diagnostic techniques."); see
18 also 20 C.F.R. § 416.928(a)-(c); Ball v. Massanari, 254 F.3d 817,
19 823 (9th Cir. 2001) ("[I]f the claimant's ailment does not pass
20 step 2, . . . it is not disabling.").

21 2. The ALJ did not err in determining Plaintiff's RFC

22 Plaintiff argues that the ALJ's RFC finding was in error
23 because it excluded limitations related to Plaintiff's peripheral
24 neuropathy, including that he "could not stand/walk for 6 of 8
25 hours" and required unscheduled work breaks that would preclude
26 full-time competitive employment. (J. Stip. at 7.)

27 As explained above, the ALJ did not err in holding that
28 Plaintiff failed to establish peripheral neuropathy as a

1 medically determinable impairment. The lack of objective medical
2 evidence of peripheral neuropathy excludes its consideration in
3 the determination of Plaintiff's RFC.³⁶ See McLavey v. Astrue,
4 325 F. App'x 593, 594 (9th Cir. 2009) ("A claimant's RFC must
5 take into account 'only limitations and restrictions attributable
6 to medically determinable impairments.'" (citing SSR 96-8P, 1996
7 WL 374184 (July 2, 1996))); Allison v. Astrue, 425 F. App'x 636,
8 639 (9th Cir. 2011) (same); Bayliss v. Barnhart, 427 F.3d 1211,
9 1217 (9th Cir. 2005) ("Preparing a function-by-function analysis
10 for medical conditions or impairments that the ALJ found neither
11 credible nor supported by the record is unnecessary.").

12 Accordingly, Plaintiff is not entitled to relief on this claim.

13 B. The ALJ Properly Evaluated Plaintiff's Credibility

14 Plaintiff argues that the ALJ failed to provide clear and
15 convincing reasons for discrediting portions of Plaintiff's
16 testimony. (J. Stip. at 11.) Plaintiff asserts that the ALJ was
17 not permitted to discredit Plaintiff's testimony solely because
18 it was unsupported by objective medical evidence. (Id. at 12.)

19
20 ³⁶ Further, even if Plaintiff had presented objective
21 evidence of peripheral neuropathy, the ALJ properly found that
22 Plaintiff received only routine, conservative treatment for the
23 alleged ailment (AR 16), implying that any symptoms were
24 adequately controlled with medication. See 20 C.F.R.
25 § 416.929(c)(3)(iv)-(v) (ALJ may consider effectiveness of
26 medication in evaluating severity and limiting effects of
27 impairment); Warre v. Comm'r of Soc. Sec. Admin., 439 F.3d 1001,
28 1006 (9th Cir. 2006) ("Impairments that can be controlled
effectively with medication are not disabling for the purpose of
determining eligibility for [Social Security] benefits."). No
evidence in the record supported more restrictive functional
limitations than the ALJ assessed. (AR 16); cf. Lewis v. Astrue,
498 F.3d 909, 911 (9th Cir. 2007) (step-two error harmless when
ALJ accounts for resulting limitations later in sequential
evaluation process.)

1 Plaintiff disputes the ALJ's assessment that his testimony
2 reflected "somewhat normal" daily activities. (Id. at 13.)
3 Reversal is not warranted on these grounds.

4 An ALJ's assessment of pain severity and claimant
5 credibility is entitled to "great weight." See Weetman v.
6 Sullivan, 877 F.2d 20, 22 (9th Cir. 1989); Nyman v. Heckler, 779
7 F.2d 528, 531 (9th Cir. 1986). "[T]he ALJ is not required to
8 believe every allegation of disabling pain, or else disability
9 benefits would be available for the asking, a result plainly
10 contrary to 42 U.S.C. § 423(d)(5)(A)." Molina, 674 F.3d at 1112.
11 In evaluating a claimant's subjective symptom testimony, the ALJ
12 engages in a two-step analysis. See Lingenfelter, 504 F.3d at
13 1035-36. "First, the ALJ must determine whether the claimant has
14 presented objective medical evidence of an underlying impairment
15 [that] could reasonably be expected to produce the pain or other
16 symptoms alleged." Id. at 1036 (internal quotation marks
17 omitted). If such objective medical evidence exists, the ALJ may
18 not reject a claimant's testimony "simply because there is no
19 showing that the impairment can reasonably produce the *degree* of
20 symptom alleged." Smolen, 80 F.3d at 1282 (emphasis in
21 original). When the ALJ finds a claimant's subjective complaints
22 not credible, the ALJ must make specific findings that support
23 the conclusion. See Berry v. Astrue, 622 F.3d 1228, 1234 (9th
24 Cir. 2010). Absent affirmative evidence of malingering, those
25 findings must provide "clear and convincing" reasons for
26 rejecting the claimant's testimony. Lester, 81 F.3d at 834. If
27 the ALJ's credibility finding is supported by substantial
28 evidence in the record, the reviewing court "may not engage in

1 second-guessing." Thomas, 278 F.3d at 959.

2 Reversal is not warranted based on the ALJ's alleged failure
3 to make proper credibility findings or properly consider
4 Plaintiff's subjective symptoms. As discussed above, the ALJ's
5 evaluation of the medical evidence was consistent with the
6 record; her rejection of Plaintiff's testimony to the extent it
7 was inconsistent with the objective evidence was therefore
8 proper. See Carmickle v. Comm'r, Soc. Sec. Admin., 533 F.3d
9 1155, 1161 (9th Cir. 2008) ("Contradiction with the medical
10 record is a sufficient basis for rejecting the claimant's
11 subjective testimony."); Lingenfelter, 504 F.3d at 1040 (in
12 determining credibility, ALJ may consider "whether the alleged
13 symptoms are consistent with the medical evidence"). Although
14 Plaintiff is correct that the ALJ was not permitted to rely on a
15 lack of objective medical evidence "alone" to discredit
16 Plaintiff's testimony (J. Stip. at 12), here the ALJ properly
17 considered it as one factor in her evaluation. See Burch v.
18 Barnhart, 400 F.3d 676, 681 (9th Cir. 2005) ("Although lack of
19 medical evidence cannot form the sole basis for discounting pain
20 testimony, it is a factor that the ALJ can consider in his
21 credibility analysis."); Kennelly v. Astrue, 313 F. App'x 977,
22 979 (9th Cir. 2009) (ALJ may not disregard testimony "solely"
23 because it was unsubstantiated by medical evidence but "may use
24 the medical evidence . . . as one factor in his evaluation").

25 The ALJ specifically identified various inconsistencies
26 between Plaintiff's testimony and the objective medical evidence
27 of his ailments. She found that although Plaintiff testified
28 that he visited the emergency room every three months (AR 457),

1 the medical records revealed less frequent medical interventions
2 (AR 16). The ALJ noted that although Plaintiff testified that
3 peripheral neuropathy affected his ability to work because it
4 interfered with his walking, causing sharp pain, tingling, and
5 numbness that made him stumble, Plaintiff confirmed that he did
6 not use a cane or walker. (AR 15.) Indeed, the hospitals
7 repeatedly found that he was not at risk of falling. (AR 231,
8 361.) The ALJ also noted that Plaintiff's complaints of vision
9 problems were unsupported by the medical evidence in the record,
10 a finding Plaintiff does not challenge. (AR 16.) Indeed, as the
11 ALJ noted, "there is no medical source statement from an
12 examining or treating physician that endorses the extent of
13 Plaintiff's alleged functional limitations." (Id.) The ALJ thus
14 properly discounted Plaintiff's statements because they either
15 were not supported by or were contradicted by the record.
16 Carmickle, 533 F.3d at 1161; Lingenfelter, 504 F.3d at 1040.

17 Moreover, as the ALJ noted, Plaintiff testified that he was
18 able to do basic daily activities, including maintaining personal
19 hygiene, dressing himself, and cooking. (AR 15.) She noted
20 Plaintiff's testimony that he was able to apply for jobs with the
21 help of his nephew and others. (Id.) During the hearing the ALJ
22 observed that one of Plaintiff's hospitalizations occurred after
23 he got overheated while "working outside" on a hot day, further
24 indicating that he was not as impaired as he claimed. (AR 460.)
25 The ALJ also noted that Plaintiff's lack of a driver's license
26 was not due to health issues but to a suspension that Plaintiff
27 had chosen not to remedy. (AR 15-16.) That Plaintiff's
28 allegations of disabling functional limitations were inconsistent

1 with evidence in the record as to his daily activities was a
2 valid reason for the ALJ to discount his testimony. See Molina,
3 674 F.3d at 1113 (“Even where [claimant’s] activities suggest
4 some difficulty functioning, they may be grounds for discrediting
5 the claimant’s testimony to the extent that they contradict
6 claims of a totally debilitating impairment.”); see also Fair v.
7 Bowen, 885 F.2d 597, 603 (9th Cir. 1989) (“[I]f, despite his
8 claims of pain, a claimant is able to perform household chores
9 and other activities that involve many of the same physical tasks
10 as a particular type of job, it would not be farfetched for an
11 ALJ to conclude that the claimant’s pain does not prevent the
12 claimant from working.”).

13 Finally, the ALJ properly found that Plaintiff “received
14 only routine, conservative treatment for poorly controlled
15 diabetes mellitus, treated gastritis, and esophagitis.” (AR 16);
16 see 20 C.F.R. § 416.929(c)(3)(iv)-(v) (ALJ may consider
17 effectiveness of medication and nature of treatment in evaluating
18 severity and limiting effects of impairment). Indeed, although
19 the record reflected three hospital visits since the amended
20 alleged onset date, in each case Plaintiff was successfully
21 treated and discharged with medication, dietary instructions, and
22 a recommendation that he follow up with his regular medical
23 provider. (See AR 281, 301, 423.) His diabetes,
24 gastrointestinal ailments, and alleged peripheral neuropathy were
25 otherwise managed with visits to Dr. Seneviratne’s clinic, where
26 his medications were renewed or adjusted and he was encouraged to
27 augment his diet and test his blood sugar twice daily. (See 5F
28 at 1-2; AR 261, 352.)

1 Because the ALJ gave clear and convincing reasons for her
2 credibility finding and those reasons were supported by
3 substantial evidence, the Court "may not engage in
4 second-guessing." Thomas, 278 F.3d at 959. Plaintiff is not
5 entitled to reversal on this claim.

6 **VII. CONCLUSION**

7 Consistent with the foregoing, and pursuant to sentence four
8 of 42 U.S.C. § 405(g),³⁷ IT IS ORDERED that judgment be entered
9 AFFIRMING the decision of the Commissioner and dismissing this
10 action with prejudice. IT IS FURTHER ORDERED that the Clerk
11 serve copies of this Order and the Judgment on counsel for both
12 parties.

13
14
15 DATED: November 8, 2013



JEAN ROSENBLUTH
U.S. Magistrate Judge

16
17
18
19
20
21
22
23
24
25
26 _____
27 ³⁷ This sentence provides: "The [district] court shall
28 have power to enter, upon the pleadings and transcript of the
record, a judgment affirming, modifying, or reversing the
decision of the Commissioner of Social Security, with or without
remanding the cause for a rehearing."